(Total Views: 696)
Posted On: 06/10/2024 12:34:00 PM
Post# of 156084
Re: biloxiblues #144317
biloxiblues, BB,
The company bluebird bio, Inc (Ticker symbol - BLUE) has an FDA-approved gene therapy for sickle cell disease.
One of the downside risks is hematologic malignancy, and monitoring every six months is needed. The pricing is approx $2-3 million per patient. The company has negotiated payment agreements with the major government payers; I don't know those numbers.
I don't own BLUE and won't own it. I happened to see the announcement of FDA approval for a treatment of this horrible disease. The share price hardly budged with that announcement.
The company bluebird bio, Inc (Ticker symbol - BLUE) has an FDA-approved gene therapy for sickle cell disease.
One of the downside risks is hematologic malignancy, and monitoring every six months is needed. The pricing is approx $2-3 million per patient. The company has negotiated payment agreements with the major government payers; I don't know those numbers.
I don't own BLUE and won't own it. I happened to see the announcement of FDA approval for a treatment of this horrible disease. The share price hardly budged with that announcement.
(3)
(0)
